Abstract:BACKGROUND Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1) plays a crucial role in regulating insulin signaling and glucose metabolism. Mutations in the APPL1 gene have been associated with the development of maturity-onset diabetes of the young type 14 (MODY14). Currently, only two mutations [c.1655T>A (p.Leu552*) and c.281G>A p.(Asp94Asn)] have been identified in association with this disease. Given the limited understanding of MODY14, it is imperative to identify additional cases and carry out comprehensive research on MODY14 and APPL1 mutations. AIM To assess the pathogenicity of APPL1 gene mutations in diabetic patients and to characterize the functional role of the APPL1 domain. METHODS Patients exhibiting clinical signs and a medical history suggestive of MODY were screened for the study. Whole exome sequencing was performed on the patients as well as their family members. The pathogenicity of the identified APPL1 variants was predicted on the basis of bioinformatics analysis. In addition, the pathogenicity of the novel APPL1 variant was preliminarily evaluated through in vitro functional experiments. Finally, the impact of these variants on APPL1 protein expression and the insulin pathway were assessed, and the potential mechanism underlying the interaction between the APPL1 protein and the insulin receptor was further explored. RESULTS A total of five novel mutations were identified, including four missense mutations (Asp632Tyr, Arg633His, Arg532Gln, and Ile642Met) and one intronic mutation (1153-16A>T). Pathogenicity prediction analysis revealed that the Arg532Gln was pathogenic across all predictions. The Asp632Tyr and Arg633His variants also had pathogenicity based on MutationTaster. In addition, multiple alignment of amino acid sequences showed that the Arg532Gln, Asp632Tyr, and Arg633His variants were conserved across different species. Moreover, in in vitro functional experiments, both the c.1894G>T (at Asp632Tyr) and c.1595G>A (at Arg532Gln) mutations were found to downregulate the expression of APPL1 on both protein and mRNA levels, indicating their pathogenic nature. Therefore, based on the patient's clinical and family history, combined with the results from bioinformatics analysis and functional experiment, the c.1894G>T (at Asp632Tyr) and c.1595G>A (at Arg532Gln) mutations were classified as pathogenic mutations. Importantly, all these mutations were located within the phosphotyrosine-binding domain of APPL1, which plays a critical role in the insulin sensitization effect. CONCLUSION This study provided new insights into the pathogenicity of APPL1 gene mutations in diabetes and revealed a potential target for the diagnosis and treatment of the disease.

Mutant HNF-1alpha and mutant HNF-1beta identified in MODY3 and MODY5 downregulate DPP-IV gene expression in Caco-2 cells.

Activation of the Insulin Gene Promoter through a Direct Effect of Hepatocyte Nuclear Factor 4α

Dominant-negative Suppression of HNF-1α Results in Mitochondrial Dysfunction, INS-1 Cell Apoptosis, and Increased Sensitivity to Ceramide-, but Not to High Glucose-induced Cell Death

The MODY1 Gene for Hepatocyte Nuclear Factor 4α and a Feedback Loop Control COUP-TFII Expression in Pancreatic Beta Cells

Expression of mutant mRNA and protein in pancreatic cells derived from MODY3- iPS cells

Hepatocyte Nuclear Factor 4α Regulates the Expression of Pancreatic β-Cell Genes Implicated in Glucose Metabolism and Nutrient-induced Insulin Secretion

HNF4A and HNF1A exhibit tissue specific target gene regulation in pancreatic beta cells and hepatocytes

Mutation P291fsinsC in the Transcription Factor Hepatocyte Nuclear Factor-1Alpha is Dominant Negative

Down-regulation of Hepatic HNF4alpha Gene Expression During Hyperinsulinemia Via SREBPs.

Experimental Models Of Transcription Factor-Associated Maturity-Onset Diabetes Of The Young

Beta-Cell-Targeted Expression of A Dominant-Negative Hepatocyte Nuclear Factor-1 Alpha Induces A Maturity-Onset Diabetes of the Young (Mody)3-Like Phenotype in Transgenic Mice

Novel Mechanisms of Regulation of the Expression and Transcriptional Activity of Hepatocyte Nuclear Factor 4Α

Forkhead Box O1/Pancreatic and Duodenal Homeobox 1 Intracellular Translocation is Regulated by C-Jun N-Terminal Kinase and Involved in Prostaglandin E-2-Induced Pancreatic Beta-Cell Dysfunction

Reduced calcium levels and accumulation of abnormal insulin granules in stem cell models of HNF1A deficiency

Functional characterization of HNF4A gene variants identify promoter and cell line specific transactivation effects

Transcriptional Regulation of X-Box-binding Protein One (XBP1) by Hepatocyte Nuclear Factor 4α (HNF4Α) Is Vital to Beta-cell Function

Molecular mechanism of HNF-1A–mediated HNF4A gene regulation and promoter-driven HNF4A-MODY diabetes

Lysine 117 residue is essential for the function of the hepatocyte nuclear factor 1α

Novel Loss-of-Function Variant in HNF1a Induces beta-Cell Dysfunction through Endoplasmic Reticulum Stress

Hepatocyte nuclear factor 1 binding element within the promoter of microsomal triglyceride transfer protein (MTTP) gene is crucial for MTTP basal expression and insulin responsiveness.

Assessment of pathogenicity and functional characterization of APPL1 gene mutations in diabetic patients